Mutation in Cutaneous Lymphoma Linked to Poor Prognosis

Article

A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma who have a MYD88 mutation have a shorter disease-specific survival.

Micrograph of DLBCL, lymph node FNA specimen, field stain; source: Nephron, Wikimedia Commons

A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) who have a MYD88 mutation have a shorter disease-specific survival compared with patients without the mutation.

Anne Pham-Ledard, MD, of Universitaire Bordeaux, Bordeaux, France, and colleagues confirmed this association in a retrospective multicenter study of medical records from 61 patients with PCLBCL-LT diagnosed between 1988 and 2010.

“Next-generation sequencing studies identified recurring and multiple genetic alterations implicated in the oncogenesis of nodal ABC-DLBCL, contributing to the nuclear factor-κB pathway constitutive activity,” Pham-Ledard and colleagues wrote in JAMA: Dermatology. “Notably, mutations affecting the B-cell receptor signaling pathway (CD79B) and other proteins affecting the nuclear factor-κB signaling most commonly, mutations of MYD88, CARD11, and TNFAIP3/A20 have been reported.”

Pham-Ledard sought to determine if any clinical features or outcomes were associated with MYD88 status. The median age of the patients examined was 79 years and 59% were women. Fifty-eight patients were ultimately included in the study group.

Results of the analysis showed that 59% of patients had the MYD88 L265P mutation. Although patients with and without the mutation had similar characteristics at presentation, those with the mutation were more likely to be older (P = .006), and had more frequent involvement of the leg (P = .008). No differences in sex, number of skin lesions, TNM stage at diagnosis, and treatment regimens were found.

Patients with the MYD88 mutation were also shown to have shorter 3-year (65.7% vs 85.4%) and 5-year specific survival rates (60.2% vs 71.7%) compared with patients with the wild-type allele.

In addition, patients with the mutations had a shorter disease-specific survival rates in both univariate (P = .03) and multivariate analysis (P = .02).

“Mutation of MYD88 predicts a poorer outcome considering MYD88 signaling and nuclear factor-κB pathway activation as actionable targets,” the researchers wrote. “Therapeutic strategies targeting either B-cell receptor signaling (as ibrutinib, the Bruton tyrosine kinase inhibitor, or fostamatinib targeting the spleen tyrosine kinase), or the interferon regulatory factor-4 and the transcription factor Spi-B (targeted by lenalidomide), or NF-κB proteasome inhibitor (bortezomib), or MYD88 inhibitors, seem promising in ABC-DLBCL and especially in PCLBCL-LT.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content